Nanologica Ab · OMXSTO:NICA
Nanologica Ab — Q3 2021 Earnings Presentation
20 slides from Nanologica Ab's earnings presentation, Oct 29, 2021
Slide 1: Interim Report Jan-Sep 2021
INTERIM REPORT JAN - SEP 2021 Nanologica AB (publ) Translation
Slide 2: Period in Brief / Financial Summary
PERIOD IN BRIEF FINANCIAL SUMMARY Net sales TSEK 2,119 Net sales for the third quarter amounted to TSEK 2,119 (2,089) and for the nine-month period to TSEK 12,238 (10,064) SIGNIFICANT EVENTS IN THE THIRD QUARTER Operating result TSEK -11,718 The operating result for the quarter amounted to TSEK -11,
Slide 3: Focus on Production! CEO comments
FOCUS ON PRODUCTION! Net sales for the quarter increased marginally to makes it a natural step to streamline our Drug TSEK 2,119, most of which again is derived from Development strategy and focus our resources to our partner project with Vicore Pharma. The inhalation. In line with this, as we annou
Slide 4: Nanologica in Brief
NANOLOGICA IN BRIEF Nanologica manufactures, develops and sells The goal is to create long-term values both with nanoporous silica particles for applications within own assets, as well as together with partners. life science. Nanologica is world-leading in controlling the shape, size, porosity, and
Slide 5: Business Area Chromatography
The agreement has expired and Nanologica, for the quarter amounted to TSEK 771 (396) and together with AIC, has chosen to not use the for the nine-month period to TSEK 1,302 (3,239). possibility of extension. The US market is now The revenue is mainly derived from the sales of covered by Nanologica'
Slide 6: Business Area Drug Development
strategy in the drug development business area streamlining the use of plant protection products being streamlined to focus on inhalation and to reduce environmental impact, the evaluation respiratory diseases, as well as the commercial project for one of two substances has been conditions for NIC-0
Slide 7: Operating Income and Result
OPERATING INCOME AND The result after tax for the quarter amounted to The book value of right-of-use assets amounted As per September KOMMANDE RAPPORTTILLFÄLLEN 30, 2021, cash and cash TSEK -12,546 (-5,899) and for the nine-month to TSEK 26,719 compared to TSEK 29,428 at the Delårsrapport equivalent
Slide 8: Employees, Organization, Patents, Partnerships
KOMMANDE RAPPORTTILLFÄLLEN partners. In addition to financial compensation, Actual outcomes may differ from these Delårsrapport parent companykvartal 1 group and the 24 apr 2020 EMPLOYEES AND ORGANIZATION Nanologica benefits from the expertise that the statements. Internal and external factors can D
Slide 9: The Share and Owners
ACCOUNTING AND VALUATION KOMMANDE RAPPORTTILLFÄLLEN Delårsrapport kvartal 1 24 apr 2020 THE SHARE AND OWNERS PRINCIPLES Delårsrapport kvartal 2 21 aug 2020 Nanologica's share is listed on Spotlight Next, a to 28,165,826 and the market capitalization was The group's accounting principles are based on
Slide 10: Financial Calendar, Auditors Review, Assurance
Compiled related party transactions during the FINANCIAL CALENDAR nine-month period: Year-end report 2021 Jan 31, 2022 Annual report 2021 Apr 8, 2022 • Costs of TSEK 1,311 relating to interest and Interim report Jan-Mar 2021 Apr 29, 2022 arrangement costs for loans taken out by Flerie Invest AB. Ref
Slide 11: Financial Statements and Notes
FINANCIAL STATEMENTS AND NOTES Statement of comprehensive income 12 Consolidated financial position 12 Consolidated statement of changes in equity 13 Consolidated statement of cashflow 13 Group quarterly data 14 Income statement parent company 14 Financial position, parent company 15 Changes in equi
Slide 12: Statement of Comprehensive Income
Statement of comprehensive income 2021 2020 2021 2020 2020 2021 2020 2020 (TSEK) Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Consolidated financial position (TSEK) Sep 30 Sep 30 Dec 31 Operating income ASSETS Net sales 2 119 2 089 12 238 10 064 16 135 Change in inventory, finished goods -910 1
Slide 13: Consolidated Financial Position, Equity and Cash Flow
2021 2020 2020 Consolidated statement of cash flow 2021 2020 2021 2020 2020 Consolidated financial position (TSEK) Sep 30 Sep 30 Dec 31 (TSEK) Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Operating activities EQUITY AND LIABILITIES Operating profit/loss -11 718 -5 795 -26 580 -15 924 -19 571 Ad
Slide 14: Group Quarterly Data and Parent Company Income Statement
Income statement parent company 2021 2020 2021 2020 2020 Group quarterly data 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 (TSEK) Jul - Sep Jul - Sep* Jan - Sep Jan - Sep* Jan - Dec Statement of comprehensive income Operating income Net sales 2 119 4 497 5 622 6 071 2 089 4 321 3
Slide 15: Financial Position, Parent Company
2021 2020 2020 2021 2020 2020 Financial position, parent company (TSEK) 30 Sep 30 Sep* 31 dec Financial position, parent company (TSEK) 30 Sep 30 Sep* 31 dec ASSETS EQUITY AND LIABILITIES Noncurrant assets Equity Share capital 11 549 11 357 11 389 Intangible assets Ongoing issues 0 32 7 Capitalized
Slide 16: Statement of Cash Flows, Parent Company
Statement of cash flows, parent 2021 2020 2021 2020 2020 company (TSEK) Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Operating activities Operating profit/loss -11 826 -7 019 -27 861 -17 628 -22 152 Adjustment for items not affecting cash flow 3 498 2 155 8 141 4 073 6 271 Interest paid -635 -3
Slide 17: Notes: Segments
NOTE 4 SEGMENTS An operating segment is part of a group that conducts operations from which it can generate revenue and incur costs, and for which independent financial information is available. The group's division into operating segments is consistent with the internal reports that the group's hig
Slide 18: Note 5 Transition to IFRS and Segment Sales
2021 Jan - Sep Composition of net sales, region 2021 2020 2021 2020 2020 Business Chroma DD support Total (TSEK) Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Net sales 1 302 10 294 642 12 238 Chromatography 771 396 1 302 3 239 4 467 Raw materials, consumables and change in inventory -1 713 -4 1
Slide 19: Effect of Changed Accounting Principle
• including the third quarter 2020, sales and earnings will decrease by TSEK 250/quarter. For the full 09-30-20 According to year 2019, sales and earnings will decrease by TSEK 1,000 and for 2020, the reduction will be TSEK previous 750. accounting Effect of changed accounting principle principles A
Slide 20: Nanologica AB contact details
Nanologica AB Forskargatan 20G 151 36 Södertälje 08 410 749 49 info@nanologica.com www.nanologica.com